Jean Pierre Garnier - Aug 19, 2024 Form 4 Insider Report for BioAge Labs, Inc. (BIOA)

Role
Director
Signature
/s/ Dov A. Goldstein as attorney-in-fact
Stock symbol
BIOA
Transactions as of
Aug 19, 2024
Transactions value $
$0
Form type
4
Date filed
9/27/2024, 04:18 PM
Previous filing
Apr 19, 2024
Next filing
Sep 25, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIOA Stock Option (Right to Buy) Award $0 +15K $0.00 15K Sep 25, 2024 Common Stock 15K $18.00 Direct F1
transaction BIOA Stock Option (Right to Buy) Award $0 +142K $0.00 142K Aug 19, 2024 Common Stock 142K $10.72 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date.
F2 This option award represents an equity security previously reported on the reporting person's Form 3, which was acquired through an exempt transaction with the Issuer prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a).
F3 The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on September 20, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Additionally, the entire award is exercisable at any time pursuant to an early exercise feature of the option award.